Comprehensive structural and functional analysis of hVEGFR1: Insights into phosphorylation, molecular interactions, and potential inhibitors through docking and dynamics simulations

Vascular Endothelial Growth Factor Receptor 1 (VEGFR1), is an enzyme with tyrosine kinase activity that plays a pivotal role in angiogenesis, the process of new blood vessel formation. This receptor is of significant clinical importance as it is implicated in various cancers, particularly non-small cell lung cancer (NSCLC), where its dysregulation leads to uncontrolled cell growth through ligand-induced phosphorylation. While commercially available drugs target VEGFR1, their prolonged use often leads to drug resistance and the emergence of mutations in cancer patients. To address these challenges, researchers have identified the human tyrosine kinase (hTK) domain of VEGFR1 as a potential therapeutic marker for lung malignancies. The 3D crystal structure of the hTK domain, obtained from Protein Data Bank (PDB ID: 3HNG), has provided vital structural insights of hVEGFR1. This study has revealed variations within the hVEGFR1 tyrosine kinase domain, distinguishing between regions associated with phosphorylase kinase and transferase activities. We identified numerous potential phosphorylation sites within the TK domain, shedding light on the protein's regulation and signaling possible. Detailed molecular interaction analyses have elucidated the binding forces between lead molecules and hVEGFR1, including hydrogen bonds, electrostatic, hydrophobic, and π-sigma interactions. The stability observed during molecular dynamics simulations further underscores the biological relevance of these interactions. Furthermore, docked complexes has highlighted localized structural fluctuations, offering insight into potential allosteric effects and dynamic conformational changes induced by lead molecules. These findings not only provide a comprehensive characterization of hVEGFR1 but also pave the way for the development of targeted therapies. Eventually, this study has the potential in identifying drug to combat diseases associated with hVEGFR1 dysregulation, including cancer and angiogenesis-related disorders, contributing to effective treatment strategies.

The defect of both angiogenesis and lymphangiogenesis is involved in preeclampsia

INTRODUCTION

Pre-eclampsia (PE) is characterized by failed remodeling of maternal vessels perfusing the placenta. Blood vessels and lymphatic system are involved in vessel remodeling and flow homeostasis in the uterus during pregnancy. This study aims to investigate the involvement of angiogenesis and lymphangiogenesis in PE.

METHODS

Placental and decidual tissues were obtained from pregnancies with PE (n = 90), including PE cases with decidual vasculopathy (DV) (n = 52) and without DV (n = 38), and healthy pregnancies (control, n = 20). The clinical characteristics of these groups were analyzed. The expression levels of VEGF1, CD34, PROX-1, VEGFR3, and CD31 in the placenta and decidua were detected through immunohistochemistry, reverse-transcription polymerase chain reaction, and Western blot.

RESULTS

The lymphangiogenic markers PROX-1 and VEGFR3 were negatively expressed in the placenta but positively expressed in the decidua. The expression levels of the angiogenic markers VEGF1 and CD34 and the panendothelial marker CD31 were significantly lower in the placenta and decidua of the PE group than in those of the control group. The expression levels of VEGF1, CD34, and CD31 were significantly lower in the placenta and decidua with DV than in those without DV. Furthermore, the expression trends of PROX-1 and VEGFR3 was similar to those of VEGF1, CD34, and CD31 among the groups.

CONCLUSIONS

Lymphangiogenesis occurred in the decidua but not in the placenta. Impaired angiogenesis and lymphangiogenesis were associated with PE, particularly in the presence of DV.